Bristol-Myers Must Face Celgene Deal Suit In NJ State Court [Law360: Mergers & Acquisitions]

By Bill Wichert (September 23, 2022, 4:22 PM EDT) — A New Jersey federal judge has sent back to state court class claims alleging Bristol-Myers Squibb Co. misled investors with respect to its $74 billion acquisition of Celgene Corp., dealing another blow to the pharmaceutical giant after it recently lost its bid to keep a similar case in New York federal court….

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

• Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
• Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
• Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS